Compare ASIX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIX | CTNM |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 507.0M |
| IPO Year | 2016 | 2024 |
| Metric | ASIX | CTNM |
|---|---|---|
| Price | $18.68 | $13.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.00 | $19.80 |
| AVG Volume (30 Days) | ★ 356.6K | 174.8K |
| Earning Date | 05-22-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 11.11 | 0.46 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,684,625,000.00 | N/A |
| Revenue This Year | $3.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.93 | ★ N/A |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $3.35 |
| 52 Week High | $25.53 | $16.33 |
| Indicator | ASIX | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 41.08 |
| Support Level | $17.54 | $10.17 |
| Resistance Level | $19.68 | $16.17 |
| Average True Range (ATR) | 1.18 | 0.98 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 38.07 | 5.43 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.